10 Low Risk High Reward Stocks Set to Triple by 2030

7. Prothena Corporation plc (NASDAQ:PRTA)

Number of Hedge Fund Holders: 17

Potential upside: 545.80%

Prothena Corporation plc (NASDAQ:PRTA) is developing treatments for diseases caused by protein problems, including AL amyloidosis, Parkinson’s, and Alzheimer’s. The company’s main pipeline drug, birtamimab, is in Phase 3 trials (AFFIRM-AL) for severe AL amyloidosis, with earlier studies showing it cut death risk by 59%. The company expects to see final results from the AFFIRM-AL trial in Q2 2025, with possible U.S. release in 2026, helping about 5,000 American patients who currently have few options.

For Alzheimer’s, Prothena is testing PRX012, an anti-amyloid beta antibody, in the Phase 1 ASCENT trial, with results expected to come mid-2025. The company is also moving forward with PRX123, a dual Aβ-Tau vaccine, as it cleared an IND and is set to enter clinical stages.

Furthermore, the company has established smart partnerships as it is working with Roche on a Parkinson’s treatment and with Bristol Myers Squibb on other therapies. Financially, the company is in good shape with $472.2 million in cash and no debt at the end of 2024. Prothena Corporation plc (NASDAQ:PRTA) also expects to have about $301 million in cash left by late 2025.

With several big trials in process, a strong financial sheet, and diverse projects, Prothena Corporation plc (NASDAQ:PRTA) is set for growth. Its upcoming results and potential drug launch make the company one of the best low risk stocks, with good potential rewards for investors.